FDA Orange Book
Generic for Levoxyl
Levoxyl contains levothyroxine. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
Yes. The generic name for Levoxyl is levothyroxine. 7 companies hold an active FDA approval (ANDA) for a generic version in the Orange Book. Therapeutic equivalence codes: AB1,AB2,AB3, AB1,AB2,AB3,AB4, AB2, AB4. Generics match 11 of the 12 Levoxyl products the Orange Book lists.
Run it in Rivvi
Map Levoxyl and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Levoxyl products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| tablet, oral | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | Marketed (Rx) | AB1,AB3 | 7 | AB1,AB2,AB3,AB4, AB1,AB2,AB3, AB4, AB2 |
| tablet, oral | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | Marketed (Rx) | AB1,AB3 | 7 | AB1,AB2,AB3,AB4, AB1,AB2,AB3, AB4, AB2 |
| tablet, oral | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | Marketed (Rx) | AB1,AB3 | 7 | AB1,AB2,AB3,AB4, AB1,AB2,AB3, AB4, AB2 |
| tablet, oral | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | Marketed (Rx) | AB1,AB3 | 7 | AB1,AB2,AB3,AB4, AB1,AB2,AB3, AB4, AB2 |
| tablet, oral | 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | Marketed (Rx) | AB1,AB3 | 7 | AB1,AB2,AB3,AB4, AB1,AB2,AB3, AB4, AB2 |
| tablet, oral | 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | Marketed (Rx) | AB1,AB3 | 7 | AB1,AB2,AB3,AB4, AB1,AB2,AB3, AB4, AB2 |
| tablet, oral | 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | Marketed (Rx) | AB1,AB3 | 7 | AB1,AB2,AB3,AB4, AB1,AB2,AB3, AB4, AB2 |
| tablet, oral | 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | Marketed (Rx) | AB1,AB3 | 7 | AB1,AB2,AB3,AB4, AB1,AB2,AB3, AB4, AB2 |
| tablet, oral | 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | Marketed (Rx) | AB1,AB3 | 7 | AB1,AB2,AB3,AB4, AB1,AB2,AB3, AB4, AB2 |
| tablet, oral | 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | Marketed (Rx) | AB1,AB3 | 7 | AB1,AB2,AB3,AB4, AB1,AB2,AB3, AB4, AB2 |
| tablet, oral | 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | Marketed (Rx) | AB1,AB3 | 7 | AB1,AB2,AB3,AB4, AB1,AB2,AB3, AB4, AB2 |
| tablet, oral | 0.3MG | Discontinued | None | 0 | None |
NDA 021301, held by KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT LLC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Approved generic levothyroxine
| Company | ANDA | TE code | Approved | Strengths |
|---|---|---|---|---|
| MYLAN PHARMACEUTICALS INC | 076187 | AB1,AB2,AB3,AB4 (A-rated, therapeutically equivalent) | June 5, 2002 | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium |
| LUPIN INC | 209713 | AB1,AB2,AB3 (A-rated, therapeutically equivalent) | January 18, 2019 | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium |
| ACCORD HEALTHCARE INC | 212399 | AB1,AB2,AB3,AB4 (A-rated, therapeutically equivalent) | October 19, 2020 | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium |
| WATSON LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC | 207588 | AB1,AB2,AB3,AB4 (A-rated, therapeutically equivalent) | May 10, 2022 | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium |
| MACLEODS PHARMACEUTICALS LTD | 211417 | AB1,AB2,AB3,AB4 (A-rated, therapeutically equivalent) | December 21, 2022 | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium |
| ASCENT PHARMACEUTICALS INC | 215259 | AB4 (A-rated, therapeutically equivalent) | January 18, 2023 | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium |
| ALEMBIC PHARMACEUTICALS LTD | 216370 | AB2 (A-rated, therapeutically equivalent) | May 20, 2026 | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium, 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium |
Levoxyl NDC codes
Questions
Is there a generic for Levoxyl?
Yes. The generic name for Levoxyl is levothyroxine. 7 companies hold an active FDA approval (ANDA) for a generic version in the Orange Book. Therapeutic equivalence codes: AB1,AB2,AB3, AB1,AB2,AB3,AB4, AB2, AB4. Generics match 11 of the 12 Levoxyl products the Orange Book lists.
What is the generic name for Levoxyl?
The active ingredient in Levoxyl is levothyroxine, per the FDA Orange Book.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.
More on Levoxyl and Levothyroxine
- What is Levoxyl used for?FDA label uses
- Is Levoxyl a controlled substance?Federal schedule
- What is Levothyroxine used for?FDA label uses
- Is Levothyroxine a controlled substance?Federal schedule
- Generic for TirosintFDA Orange Book
- Generic for ThyquidityFDA Orange Book
- Generic for Tirosint-solFDA Orange Book
- Generic for Levo-tFDA Orange Book
- Generic for LevoletFDA Orange Book
- Generic for SynthroidFDA Orange Book
- Generic for Thyro-tabsFDA Orange Book
- Generic for UnithroidFDA Orange Book
- L-Thyroxines listFDA drug class
- Levoxyl Medicare Part D coverageBy plan and state
- NDC 60793-850Levoxyl NDC record
- NDC 60793-851Levoxyl NDC record